Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is China Biotech Services Holdings Quick Ratio?
China Biotech Services HoldingsHKSE:08037 -1.54%19 Quick Ratio is 0.12 as of Dec. 2025, which is 92% below its 10-year median of 1.58. GuruFocus rates HKSE:08037 with a GF Score™ of 19/100 and a GF Value™ of HK$0.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, China Biotech Services Holdings ranks worse than 94.84% on this metric.
China Biotech Services Holdings has a quick ratio of 0.12. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for China Biotech Services Holdings's Quick Ratio or its related term are showing as below:
HKSE:08037'
s Quick Ratio Range Over the Past 10 Years
Min: 0.12 Med: 1.58 Max: 13.54
Current: 0.12
During the past 13 years, China Biotech Services Holdings's highest Quick Ratio was 13.54. The lowest was 0.12. And the median was 1.58.
HKSE:08037's Quick Ratio is ranked worse than 94.84% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.74
vs HKSE:08037: 0.12
China Biotech Services Holdings (HKSE:08037) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
China Biotech Services Holdings Quick Ratio Related Terms
China Biotech Services Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:08037 vs TMO, DHR, IDXX: Quick Ratio Comparison
For the Diagnostics & Research subindustry, China Biotech Services Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biotech Services Holdings Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where China Biotech Services Holdings's Quick Ratio falls into.
China Biotech Services Holdings Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings (HKSE:08037) has a Quick Ratio of 0.12 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on China Biotech Services Holdings and its competitors. This is 92% below median its historical median of 1.58. Over the past decade, China Biotech Services Holdings' Quick Ratio has ranged from 0.12 to 13.54. According to the industry distribution chart, China Biotech Services Holdings ranks #202 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 94.8%.
Is China Biotech Services Holdings' Quick Ratio too high?
China Biotech Services Holdings' current Quick Ratio of 0.12 is 92% below median its 10-year median of 1.58. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 13.54. The Medical Diagnostics & Research industry median Quick Ratio is 1.74. China Biotech Services Holdings' value of 0.12 is 93.1% below this industry median. Based on the distribution chart, China Biotech Services Holdings ranks #202 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #202 out of 213 companies for Quick Ratio. This places China Biotech Services Holdings in the lower half of its industry. The industry median Quick Ratio is 1.74. China Biotech Services Holdings' value of 0.12 is 93.1% below this benchmark. Historically, China Biotech Services Holdings' own Quick Ratio has ranged from 0.12 to 13.54 over the past decade. While the company's 10-year median is 1.58 vs. the industry median of 1.74, China Biotech Services Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.74, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Biotech Services Holdings's current Quick Ratio of 0.12 is 93.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current Quick Ratio is 0.12, which is 92% below median its own 10-year median of 1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$0.64 — trading 137% above its estimated fair value. The current Quick Ratio is 0.12, which is 92% below median its 10-year median of 1.58 and 93.1% below the Medical Diagnostics & Research industry median of 1.74. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current Quick Ratio is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?
Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued.
The current stock price of HK$0.64 is trading 137% above its estimated GF Value™ of HK$0.27.
GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08037:
Quick Ratio: 0.12 (92% below median its 10-year median of 1.58)
GF Value™: HK$0.27 vs. price of HK$0.64 (137% above fair value)
Industry Position: 93.1% below the Medical Diagnostics & Research median (#202 of 213)
No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Biotech Services Holdings Business Description
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score
Get the complete analysis for HKSE:08037
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08037 has been successfully added to your 
